Torben Straight Nissen, MSc, PhD
Dr. Torben Straight Nissen is Managing Director/Head of Portfolio Management and Development Strategy. He has provided leadership to global R&D organizations in the pharmaceutical and biotech industries for more than 10 years and has advanced several products from idea to clinical proof of concept. As Managing Director/Head of Portfolio Management and Development Strategy of Pfizer's Centers for Therapeutic Innovation, he is part of Pfizer's new entrepreneurial efforts to develop highly innovative and differentiated therapeutics by integrating groundbreaking research from leading medical institutions with Pfizer's significant drug development expertise.
Prior to joining Pfizer, Dr. Straight Nissen served as Chief Operating Officer of Ascendis Pharma. In this position, he was responsible for advancing the company's portfolio of new innovative prodrugs from early preclinical proof of principle to commercialization. He joined Ascendis Pharma from a position as Senior Vice President of Moksha8 Pharmaceuticals and President of Moksha8 Biosimilars where he built and advanced its portfolio of biosimilar products. Earlier, Dr.
Straight Nissen was at Maxygen from 2000 to 2007 where he held several leadership positions, including Managing Director for Maxygen's Danish R&D operations and Senior Vice President of Global Project Management.
He began his pharmaceutical career at Novo Nordisk with a focus on protein engineering.
Dr. Straight Nissen obtained his M. Sc. in chemical engineering from the Technical University of Denmark and his Ph.D. from Carlsberg Laboratories and the Technical University of Denmark.
Pfizer's Centers for Therapeutic Innovation
Translating Leading Science into Clinical Candidates Through Networked Collaboration
The Centers for Therapeutic Innovation (CTI), a newly created, entrepreneurial Research Unit at Pfizer, Inc. is dedicated to the establishment of global partnerships between Academic Medical Centers (AMCs) and Pfizer to transform research and development through a focus on translational medicine.
The CTI collaborative model will effectively and efficiently combine the best ideas, research and expertise of the AMC with Pfizer's resources. The result of this integration will be better testing of clinical hypotheses, increasing the speed with which we establish Proof-of-Mechanism (PoM) and ultimately bring truly differentiated medicines to patients in need.